In order to use buprenorphine as an analgesic in immunological experiments, we have studied the potential immunotoxicity of buprenorphine. Three-week-old male Wistar Riv: TOX rats were subcutaneously treated with buprenorphine by injection of 0.1, 0.4, or 1.6 mg/kg body weight per day over a period of 4 weeks. Concentrations used were within the range for analgesia in rats. A slight decrease of body weight gain was observed at the highest dose in one but not in a duplicate study. Decreased liver weights were observed in all dose groups. Histopathologically glycogen storage was decreased and fatty vacuolation was found to be increased starting from the lowest dose group. The relative but not absolute weight of the lungs was slightly increased at the lowest dose, this phenomenon was therefore not dosedependent. Histopathologically, a dose-dependent increase in interstitial pneumonia in the lung was found. At the 2 higher dose levels the weight of the adrenal glands was increased. No haematological changes were found, nor were there effects on bone marrow.
Advantages claimed for buprenorphine use in man are low abuse potential, little capacity to produce physical dependence and mild abstinence phenomena (Hanks 1987) . It is 25-40 times as potent as morphine, and the duration of analgesia is estimated between 6-9 h. For similar reasons buprenorphine is well suited for use in experimental animals.
No information is available on potential toxicity of this compound with regard to the effects on the immune system. Such effects have been reported for other opiates such as morphine and methadone. This is especially relevant if buprenorphine is to be used in immunological studies that cause pain in the experimental animals, e.g. in vivo studies of arthritis, tumour diseases, inflammatory responses, etc.
We have tested the potential immunotoxicity of buprenorphine according to the approach outlined by Van Loveren and Vos (1989) . According to this approach, a panel of immunotoxicological parameters is included in an experiment in which general toxicological parameters are determined, aimed at determining the target for toxicity. The immunotoxicological indices that we tested in this study are: routine haematology, including differential leukocyte counting, determination of total serum IgM, IgG, IgA, and IgE concentrations, bone marrow cellularity, weights and histopathology of the thymus, spleen, popliteal and mesenteric lymph nodes, natural killer cell activity and mitogen responsiveness of spleen lymphoid cells.
Materials and methods

Animals
Male Wistar rats /Riv: TOX, 35-50 g) at weanling age were obtained from the breeding stock of our institute. The animals were randomly distributed and were housed under conventional conditions in pairs in macrolon cages type IV on sawdust (free of toxic compounds). Standard rat feed [RMH-B)and tap water were available ad libitum. In the animal Van Loveren et al. room a light-dark regimen of 12h was maintained (light on from 07:00 until 19:00). Temperature and humidity were recorded and maintained at 20°C ± 1 and. 45-65% relative humidity. An acclimatization period of one week was observed.
Buprenorphine
Buprenorphine hydrochloride was obtained from Reckitt and Colman Pharmaceuticals [Hull, UK) as a powder. The total amount was dissolved in physiological saline with 5% dextrose. This stock solution was divided into smaller portions and frozen. Weekly, fresh solutions were prepared from this stock, and administered to the rats.
Experimental design
Two essentially identical experiments were carried out. The first one served as a dose range-finding study, and for the second, more extended study, the original doses were decided to be adequate. In the experiments, groups of 6 or 10 rats were weighed daily and dosed according to their weight. The buprenorphine solution was administered subcutaneously (s.c.) twice a day at 08:30 and 16:30 h during 28 or 31 days. To maintain a constant exposure to buprenorphine over both night and day, the evening dose administered was two-thirds of the total daily dose and the morning dose one-third of the total daily dose. The control group received s.c. injections with the vehicle. The following doses of buprenorphine were used: group I: control; group II: 0.035 and 0.065 mg/kg body weight/ day respectively [total 0.1 mg/kg/ day); group III: 0.14 and 0.26, i.e. total O.4mg/kg/day; and group IV: 0.56 and 1.04, i.e. totaI1.6mg/kg/day.
Haematology
Under ether anaesthesia, blood was collected by retro-orbital puncture into heparinized tubes. The following haematological indices were determined: haemoglobin (Hb), haematocrit (Ht), erythrocytes [RBCl, mean volume of erythrocytes (MCV), mean Hb mass of erythrocytes (MCH), mean Hb concentration of erythrocytes (MCHCl, leukocytes (WBC) and platelets (PLT). Additionally, differential leukocyte counting was performed on blood smears.
Immunoglobulin concentrations in serum
Following blood collection for haematology, the rats were killed by exsanguination from abdominal vessels during terminal anaesthesia. Serum was collected by centrifugation of clotted blood and stored at -20°C. Total IgM, IgG, IgA and IgE concentrations in the serum were analysed by means of a 'sandwich' ELISA (enzyme-linked immunosorbent assay) as described by Vos et a1. 1982. Total IgA and IgE concentrations were analysed in an essentially similar fashion as the other classes of immunoglobulin, except that for coating of the microtitre plates monoclonal anti-rat IgA (Van Loveren et a1. 1988), or monoclonal anti-rat IgE antibodies (MARE-I, obtained from Sanbio, Uden, NL) respectively were used, whereas immunoglobulins in serum samples bound to these antibodies were detected by sheep anti-rat IgA (prepared in our own institute) or monoclonal anti-kappa chains of rat immunoglobulins (MARK-I, kindly donated by Dr J. Rozing, Leiden, NL), conjugated with peroxidase respectively.
Bone marrow
One femur was removed and the ends of the femur were removed using a scalpel. Bone marrow cells were collected by flushing 4 ml Impuls Cytometer Fluid through the femur using a 21 gauge needle. The concentration of nucleated cells was determined in a Coulter counter using 10m! of Isoton II supplemented with 3 drops saponin solution (Coulter Electronics Ltd, Luton, UK) in order to lyse erythrocytes. Additionally, a visual differential count of the cells was done in May-Grunvald Giemsa stained cytospin preparations.
Histopathology
Several organs were examined macroscopically, and weighed. The organs were weighed, fixed in 10% formalin, and embedded in paraplast. Haematoxylin-eosin 357 (HE) stained tissue sections approximately 4 J.tm thick were prepared of the following organs: liver, kidneys, adrenal glands, thyroid gland, lungs, heart, testes, brains, colon, jejunum, femur, pituitary gland, spleen, thymus, mesenteric lymph nodes, popliteal lymph nodes, and bronchial lymph nodes. Vacuolation caused by fat accumulation in liver was examined in Oil Red 0 stained tissue sections.
Mitogen responsiveness of lymphoid spleen cells
The spleen was removed aseptically and weighed as indicated earlier. Part of the spleen was not fixed in formalin, but was also weighed and kept in Iscove's complete medium (Iscove's Modified Dulbecco's medium (cat. no. 430-2200, Gibco Labs, Grand Island, NY) supplemented with 10% Foetal Calf Serum (cat. no. 01l-06290M, heat inactivated 30 min at 56°C) and 100IU/ ml penicillin and 100J.tg/ ml streptomycin. The tissue was cut into smaller pieces and these were pressed through a fine metal sieve. The suspension (in Iscove's medium) was centrifuged and the red blood cells were lysed in approximately 2 ml of lysing fluid (8.3 g NH4Cl, LOg KHC03 and 37.2g EDTA per 1 aquadest, pH= 7.2). After washing in Iscove's complete medium, the suspension was filtered through glasswool. After 3 further washings, the cells were resuspended in Iscove's medium and counted with a Coulter Counter (dilution 1: 50). The cells were brought to a concentration of 3 x 10 6 vital cells/ml. 150ftl of the cells suspension were added to the wells of a 96-wells round bottom plate [Greiner), in triplicate. Ten ILlof the mitogen solution was added per well. The mitogens used were: concavalin A (ConA, 6 ILg/ml, Janssen Chimica); phytohaemagglutinin (PHA, 1: 5 dilution of reconstituted PHA from Wellcome Diagnostics); pokeweed mitogen (PWM, 1: 20 dilution of stock solution of PWM from Gibco Laboratories), and lipopolysaccharide (LPS (LPS-WE. coli 0127: B8), 0.4 mg/ml, Difco Laboratories). Medium (10ILl)was added to the well as a control. The plates were incubated for 48 or 72 h (37°C, 5% CO 2 ), Twenty-two hours before harvesting 10 J.tl of 3H-thymidine (specific activity 5 Ci/mmol; 100J.tCi/mlj Amersham) were added to each well. After the incubation period the cells are harvested on a glass-fibre filter (Skatron Automatic Harvester, type 7019). Scintillation fluid was added to the filters and the activity was counted in a liquid scintillation counter (Betaplate 1205, LKB, Wallac, Pharmacia). All samples were tested in triplicate.
Natural killer cell activity
Spleen lymphoid cell suspensions were prepared as indicated above. Suspensions of 2 ml at a concentration of 2 x 10 7 vital cells/ml were kept overnight (37°C, 5% CO 2 ) in a 6-well plate (Costar). Then, the cells were recounted, and brought to concentrations of 2.5 x 10 6 , 5 X 10 6 and 1 x 10 7 vital cells/ml. One hundred J.tl of the cell suspensions of each concentration were added to the wells of a flat bottom 96-well plate (Costar) in triplicate. YAC lymphoma cells were radiolabelled by incubating 100 ai SlCr with 1 x 10 6 cells for 4 h at 37°C. One hundred J.tlof a suspension of 10 S/ml SlCr labelled YAC cells was added per well. The plates were incubated for 4 h (37°C, 5% CO 2 ), and were then centrifuged. The supernatant was adsorbed with cotton-wool plugs (Skatron). The content of radioactivity, a measure for chromium release, was determined in aT-counter (LKB, Wallac 1280 Ultragamma). Three controls were 
Results
Haematology
No effects on haematological parameters were found, nor was there any effect on the differential cell counts of blood smears (data not shown). ±5.56 4.10 ±0.177*** 0.89 ±0.024 0.004±0.000 1.02 ±0.021 0.298±0.012 0.440±0.019 0.083 ± 0.004*** 0.008 ± 0.0007*** (5) "Total daily subcutaneous dose of buprenorphine for 28 days beody weights are expressed in g:!:SEM; relative organ weights are expressed as percentage of individual body weights:!: SEM Analysis of variance was performed on these data n = 6. except where indicated between parentheses *=P<0.05 **=P<0.01
Immunoglobulin concentrations
The results of the 2 studies were combined. No effects of buprenorphine exposure were found on total IgM, G, and E levels. In some animals IgA concentrations were below the detection level. This did not appear to be associated with buprenorphine exposure, as some of these rats were also present in control groups, and these values were therefore excluded. Table 1 shows that buprenorphine decreased the concentration of IgA in serum at the highest dose only.
Bone marrow
A slight but not statistically significant increase in numbers of nucleated cells was found in bone marrow in the 2 highest dose groups. No effects were found in differential cell counts of bone marrow in cytocentrifuge preparations [data not shown).
Body weight and organ weights of the animals
The weight of the animals was recorded every day. In one study no differences in body weight gain were recorded, whereas in the duplicate study a slight decrease in body weights was noted (Tables 2 and 3 ).
In neither of the studies were effects noted of buprenorphine administration on the absolute (data not shown) or relative weight of the kidneys, pituitary, testes, and spleen. The absolute (data not shown) and relative weight of the liver was significantly lower in all 3 exposed groups in both experiments. In the second but not first study an increased absolute (data not shown) and relative weight of the thymus was found in all dosed groups, that was significant at the 0.05 or 0.01 level respectively, but not at the 0.001 level. In the first study, mesenteric and popliteal lymph nodes showed an increased weight pertaining to both absolute (data not shown) and relative weights of the organs in the top and middle dose group and in the top dose group respectively. In the second study no effects on the weight of the popliteal lymph nodes were observed; the weight of the mesenteric lymph nodes was not assessed.
The lung and adrenals were not removed during the first studYi in the second study the weight of the lung increased but this increase was only significant in the group that was treated with the lowest dose at the P<O.01 but not at the 0.001 level. The weight of the adrenal glands is statistically significantly increased in all treated groups Van Loveren et al. (Table 2) . As is true for all organs mentioned, effects on absolute or relative weights of the organs were not different, due to the fact the body weights in the dosed groups did not differ much from the controls. 
Histopathology
Macroscopically no effects were observed in buprenorphine dosed rats. In HE stained tissue sections of the liver parenchym, cytoplasmic vacuolation was seen. Semiquantitatively, a decrease in glycogen storage was found starting with the lowest dose group. Hepatocytes with fat accumulation were found scattered in the whole liver, also starting with the lowest dose group. An increase in fatty degeneration of the hepatocytes in the midzonal and periportal areas was found in the higher dose groups.
In the lungs some slight signs of interstitial pneumonia are observed after buprenorphine administration, as evidenced by small inflammatory cell infiltrates.
In none of the lymphoid organs were histopathological effects of buprenorphine observed, i.e. no effects on general "Total daily subcutaneous dose of buprenorphine for 31 days bOata are expressed as mean + SEM Analysisof variance was performed on these data n = 10, except where indicated between parentheses In this 4-week subcutaneous dosing study, buprenorphine administration, at a dose range that was chosen to include the range where buprenorphine is reported to have analgesic activity (FleckneIl1991), was shown to have only minor effects on the immune system. The changes recorded were increased weights of the thymus nodes in one of 2 studies, and decreased serum IgA concentrations. Other indices of the immune system were unaffected, i.e. differential cell counts of blood; bone marrow cellularity; histopathology of lymphoid organs, induding those showing altered weights; serum concentrations of IgM, G, and E. The functional parameter natural killer cell activity was also not affected by the administration of buprenorphine. An apparent stimulatory action of buprenorphine was found on mitogen responsiveness to all 4 different mitogens !pWM, LPS, ConA and PHA). Yet, none of the effects observed were statistically significant. Moreover, .the magnitude of stimulation that was found was very limited, and it is therefore unlikely that this represents a biologically significant alteration. At the concentrations of buprenorphine that caused some effects on the immune system, other toxic effects were also noted. A slight decrease in body weight was found. Besides decreased liver weights, decreased glycogen storage and accumulation of fat in hepatocytes were observed. In the lungs a slight but dosedependent increase of interstitial inflammation was found.
Taken together, these data indicate that at pharmacological dose-levels some immunotoxicological effects of buprenorphine treatment were found, but that these effects were not very pronounced, nor were they found in the absence of other toxicological effects. It is therefore possible to draw the conclusion that the immune system is not a sensitive target for toxicity of this compound. Moreover, the effects that were observed may not be direct effects of buprenorphine on the immune system, but rather indirect effects, e.g. via hormonal influence as a result of effects on the adrenal glands.
We originally hypothesized direct effects of buprenorphine on the immune system, as such effects have been reported for other opiates such as morphine and methadone. In vitro, pharmacological concentrations of morphine or methadone depress mitogen responsiveness of human T -and Blymphocytes. Also a reduction of sheep red blood cell (SRBC)-rosetting of human Tlymphocytes can be found (Fischer 1988) . In vivo, chronic administration of morphine to mice resulted in a marked atrophy of the thymus and spleen and a sustained elevation of CD4 + ICD8 + (Thelper cell IT-suppressor cell) ratios [Arora et al. 1990 ). In a study in the rat, morphine induced a dose-related increase in relative weight of the spleen, whereas the relative weight of the lymph nodes was increased after 6 weeks of oral administration of morphine or methadone (Van der Laan et a1. 1988) . Van Loveren et al. In this study, histopathologically a doserelated increase in cell density in the medullary cords of lymph nodes was observed, suggesting an effect on the humoral arm of the immune system. Morphine was shown to affect natural killer cell activity, but methadone failed to exert such effects (Shavitt et a1. 1984) . This suppression might be caused by a direct effect, via opiate receptors. Alternatively, opioids might affect natural killer cell activity indirectly by causing or modulating the release of certain cytokines, e.g. of interferon [Herberman & Ortaldo 1982) . Finally, morphine and methadone exposure may induce decreased resistance to infections [Tubaro et a1. 1983 , Tubaro et a1. 1987 It can be concluded that opiate analgesics have either direct or indirect immunomodulatory effects and that this may also be true for buprenorphine. These side effects should be considered when administering buprenorphine, especially in those experiments where the immune system is involved. In such experiments, it should be evaluated if the target organ or cells that are studied can also be affected by buprenorphine. It should also be kept in mind, that stress caused by pain may influence the immune system. Therefore, for every experiment the potential side effects of buprenorphine should be evaluated against the effects of stress.
